On February 11, 2021 H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., reported a partnership with Flatiron Health, a healthcare technology and services company focused on accelerating cancer research and improving patient care, and Foundation Medicine, a genomic insights company, to expand its use of real-world data in the research and development of drugs for the potential treatment of cancer (Press release, H3 Biomedicine, FEB 11, 2021, View Source [SID1234574953]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H3 will use Flatiron Health and Foundation Medicine’s extensive, real-world clinico-genomic database (CGDB) to accelerate its research and development efforts as well as aid in the design of clinical trials. The CGDB links comprehensive genomic profiling (CGP) data from patients who underwent CGP testing by a Foundation Medicine assay with clinical outcomes data for patients in the Flatiron Health network.

"The CGDB complements H3’s expertise in cancer genomics. We already reap the benefits of our longstanding data partnership with Foundation Medicine and this agreement is a natural extension," said Lihua Yu, Ph.D., President and Chief Data Science Officer of H3. "We are hopeful that our collaboration with Flatiron Health and Foundation Medicine will help to accelerate the development of new precision medicines for individuals living with cancer."

"The valuable insights we derive from our unique real-world data set can play a pivotal role in helping biopharma leaders like H3 accelerate research and development and bring potentially breakthrough precision medicine options to more cancer patients," said Brian Alexander, M.D., Chief Medical Officer at Foundation Medicine. "We are excited to expand our collaboration with H3, in partnership with Flatiron, reinforcing our shared commitment to deliver faster, more economical and increasingly representative evidence generation to help shape the future of patient care and outcomes."

"We’re very excited to be part of H3’s innovative, data-driven approach to precision oncology research," said Michael Vasconcelles, M.D., Chief Medical Officer at Flatiron Health. "Pairing Flatiron’s clinical data with Foundation Medicine’s CGP data can support important insights at all stages of the cancer medicine development lifecycle."

In addition to the CGDB, H3 will subscribe to Flatiron’s longitudinal, de-identified real-world dataset specific to breast cancer.